Encelta AG

Encelta has developed a groundbreaking cell therapy platform addressing key challenges in the field. Our allogeneic T-cell product is uniquely compatible with all 7 approved bispecific antibodies and 100+ molecules in clinical trials. With a production cost under $1k/patientcompared to up to $200k for existing therapiesour solution is scalable, with a single batch treating 100+ patients. The products versatility spans blood cancers, solid tumors, and autoimmune diseases, offering unprecedented potential to make cell therapy accessible, affordable, and globally impactful.